Effect of Intravesical Instillation Therapy on Cancer-specific Survival Rate of Stage T1 Non-muscle-invasive Bladder Transitional Cell Carcinoma Patients After Transurethral Resection
-
摘要:目的
研究膀胱灌注治疗对T1期非肌层浸润性膀胱移行细胞癌（BTCC）患者经尿道膀胱肿瘤切除术（TURBT）后癌症特异性生存率（CSS）的影响。
方法选取SEER数据库2010—2015年诊断为T1期非肌层浸润性BTCC患者的资料，将TURBT是否联合膀胱灌注治疗作为分组依据，并通过1:1倾向性得分匹配法匹配不同分组患者基线资料的差异，采用Kaplan-Meier法绘制生存曲线并使用Log rank检验比较两组患者总体生存率（OS）和CSS的差异，采用单因素及多因素Cox回归分析影响患者CSS的独立危险因素。
结果与无膀胱灌注治疗组相比，TURBT联合膀胱灌注治疗组OS和CSS更高（P < 0.05）。多因素Cox回归结果显示，TURBT联合膀胱灌注治疗是患者预后的保护因素（HR=0.783, 95%CI: 0.650~0.942, P < 0.01）。
结论TURBT联合膀胱灌注治疗能提高T1期非肌层浸润性膀胱移行细胞癌患者的癌症特异性生存率。
-
关键词:
- 膀胱灌注治疗 /
- T1期 /
- 膀胱癌 /
- 经尿道膀胱肿瘤切除术 /
- 倾向性得分匹配
Abstract:ObjectiveTo investigate the effect of transurethral resection of bladder tumor (TURBT) with or without intravesical instillation therapy on cancer-specific-survival rate (CSS) of T1 stage non-muscle-invasive bladder transitional cell carcinoma (BTCC) patients.
MethodsThe data of patients diagnosed with T1 stage non-muscle-invasive BTCC from 2010 to 2015 were obtained from the SEER database. The different dividing groups were based on TURBT with or without intravesical instillation therapy. A 1:1 PSM method was used to balance the differences in baseline data between each group. Herein, Kaplan-Meier methods were used to draw survival curves, and the difference between OS and CSS were compared by Log rank test. In addition, univariate and multivariate Cox regressionanalyses were used to explore the independent risk factors of CSS.
ResultsThe OS and CSS of patients in the TURBT combined with intravesical instillation therapy group were higher than those of the TURBT alone group (P < 0.05). TURBT combined with intravesical instillation therapy was a protective factor in prognosis with T1 stage non-muscle-invasive BTCC patients (HR=0.783, 95%CI: 0.650-0.942, P < 0.01).
ConclusionTURBT combined with intravesical instillation therapy improves the CSS of patients with T1 stage non-muscle-invasive BTCC.
-
Competing interests: The authors declare that they have no competing interests.作者贡献：马兰：课题设计、数据处理、论文撰写杨汝春：论文审核并对论文提出重要建议
-
![]()
图 1 PSM后两组患者OS和CSS曲线
Figure 1 Overall survival and cancer-specific survival curves of two groups after PSM
-
[1] Dobruch J, Oszczudłowski M. Bladder Cancer: Current Challenges and Future Directions[J]. Medicina (Kaunas), 2021, 57(8): 749. doi: 10.3390/medicina57080749
[2] Heath EI, Rosenberg J. The biology and rationale of targeting nectin-4 in urothelial carcinoma[J]. Nat Rev Urol, 2021, 18(2): 93-103. doi: 10.1038/s41585-020-00394-5
[3] Dyrskjøt L, Ingersoll MA. Biology of nonmuscle-invasive bladder cancer: pathology, genomic implications, and immunology[J]. Curr Opin Urol, 2018, 28(6): 598-603. doi: 10.1097/MOU.0000000000000543
[4] Babjuk M, Böhle A, Burger M, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016[J]. Eur Urol, 2017, 71(3): 447-461. doi: 10.1016/j.eururo.2016.05.041
[5] 中国研究型医院学会泌尿外科学专业委员会, 中国医疗保健国际交流促进会泌尿健康促进分会, 中国医疗保健国际交流促进会循证医学分会. 中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南(2018年标准版)[J]. 现代泌尿外科杂志, 2019, 24(7): 516-542. doi: 10.3969/j.issn.1009-8291.2019.07.004 Urological Surgery Committee of China Research Hospital Association, Urological Health Promotion Branch of China Medical and Healthcare International Exchange Promotion Association, Evidence-based Medicine Branch of China Medical and Healthcare International Exchange Promotion Association. Clinical practice Guidelines for the treatment and surveillance of Chinese non-muscle invasive bladder cancer (2018 Standard Edition)[J]. Xian Dai Mi Niao Wai Ke Za Zhi, 2019, 24(7): 516-542. doi: 10.3969/j.issn.1009-8291.2019.07.004
[6] Barman I, Dingari NC, Singh GP, et al. Selective sampling using confocal Raman spectroscopy provides enhanced specificity for urinary bladder cancer diagnosis[J]. Anal Bioanal Chem, 2012, 404(10): 3091-3099. doi: 10.1007/s00216-012-6424-6
[7] Babjuk M, Burger M, Compérat EM, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-2019 Update[J]. Eur Urol, 2019, 76(5): 639-657. doi: 10.1016/j.eururo.2019.08.016
[8] Yassaie O, Chehroudi C, Black PC. Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma[J]. Ther Adv Med Oncol, 2021, 13: 17588359211039052.
[9] Kulkarni GS, Hakenberg OW, Gschwend JE, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer[J]. Eur Urol, 2010, 57(1): 60-70. doi: 10.1016/j.eururo.2009.08.024
[10] Cumberbatch MGK, Foerster B, Catto JWF, et al. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review[J]. Eur Urol, 2018, 73(6): 925-933. doi: 10.1016/j.eururo.2018.02.014
[11] Naselli A, Hurle R, Paparella S, et al. Role of Restaging Transurethral Resection for T1 Non-muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis[J]. Eur Urol Focus, 2018, 4(4): 558-567. doi: 10.1016/j.euf.2016.12.011
[12] Brausi M, Oddens J, Sylvester R, et al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG[J]. Eur Urol, 2014, 65(1): 69-76. doi: 10.1016/j.eururo.2013.07.021
[13] Larsen ES, Joensen UN, Poulsen AM, et al. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections[J]. APMIS, 2020, 128(2): 92-103. doi: 10.1111/apm.13011
[14] Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer[J]. Nat Rev Urol, 2018, 15(10): 615-625. doi: 10.1038/s41585-018-0055-4
[15] Krajewski W, Matuszewski M, Poletajew S, et al. Are There Differences in Toxicity and Efficacy between Various Bacillus Calmette-Guerin Strains in Bladder Cancer Patients? Analysis of 844 Patients[J]. Urol Int, 2018, 101(3): 277-284. doi: 10.1159/000492722
[16] Li R, Sundi D, Zhang J, et al. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin[J]. Eur Urol, 2020, 78(3): 387-399. doi: 10.1016/j.eururo.2020.02.012
[17] Amini E. Re: The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis: C. R. Haas, L. J. Barlow, G. M. Badalato, G. J. DeCastro, M. C. Benson and J. M. McKiernan J Urol 2016; 195: 1704-1709[J]. J Urol, 2016, 196(5): 1589. doi: 10.1016/j.juro.2016.06.084
[18] 丁祥黎, 杨德林, 颜汝平, 等. 欧洲癌症研究与治疗组织评分系统对非肌层浸润性尿路上皮癌患者经尿道膀胱肿瘤电切术后吡柔比星即刻灌注化疗的效果评价[J]. 中华肿瘤杂志, 2018, 40(4): 308-312. Ding XL, Yang DL, Yan RP, et al. Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer[J]. Zhonghua Zhong Liu Za Zhi, 2018, 40(4): 308-312.
[19] Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013[J]. Eur Urol, 2013, 64(4): 639-653. doi: 10.1016/j.eururo.2013.06.003
[20] Li NC, Ye ZQ, Na YQ, et al. Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study[J]. Chin Med J (Engl), 2013, 126(15): 2805-2809.
[21] Karavana SY, Şenyiğit ZA, Çalışkan Ç, et al. Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation[J]. Drug Des Devel Ther, 2018, 12: 1959-1975. doi: 10.2147/DDDT.S164704
[22] Skinner EC, Goldman B, Sakr WA, et al. SWOG S0353: Phase Ⅱ trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin[J]. J Urol, 2013, 190(4): 1200-1204. doi: 10.1016/j.juro.2013.04.031
[23] Steinberg RL, Thomas LJ, Brooks N, et al. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer[J]. J Urol, 2020, 203(5): 902-909. doi: 10.1097/JU.0000000000000688
[24] Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma[J]. N EnglJ Med, 2017, 376(11): 1015-1026. doi: 10.1056/NEJMoa1613683
[25] Vuky J, Balar AV, Castellano D, et al. Long-Term Outcomes in KEYNOTE-052: PhaseⅡ Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer[J]. J Clin Oncol, 2020, 38(23): 2658-2666. doi: 10.1200/JCO.19.01213
[26] Seo M, Langabeer Ii JR. Demographic and Survivorship Disparities in Non-muscle-invasive Bladder Cancer in the United States[J]. J Prev Med Public Health, 2018, 51(5): 242-247. doi: 10.3961/jpmph.18.092
[27] 赵家红, 张伟, 李佳伟, 等. 非肌层浸润性膀胱癌的危险分层工具和预后模型的研究进展[J]. 肿瘤防治研究, 2020, 47(4): 309-312. http://www.zlfzyj.com/CN/abstract/abstract9580.shtml Zhao JH, Zhang W, Li JW, et al. Research Progress in Risk Stratification Tools and Prognostic Models for Non-muscle-invasive Bladder Cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2020, 47(4): 309-312. http://www.zlfzyj.com/CN/abstract/abstract9580.shtml
-
期刊类型引用(4)
1. 胡婉彦，汪溢，秦晓燕，郑志昂. 膀胱移行细胞癌患者血cGAS、STING基因表达与癌组织CD44阳性的剂量—效应关系. 疑难病杂志. 2025(02): 214-219 . 
百度学术
2. 耿改丽，连文晓，陈蕊. 个案护理对膀胱肿瘤患者自我护理能力和生命质量的影响. 齐鲁护理杂志. 2024(01): 41-44 . 百度学术
3. 韦兴发，李智强，陈从其，林云侨，陈锦添. 卡介苗灌注联合经尿道红激光汽化切除术治疗非肌层浸润性膀胱癌的效果. 国际泌尿系统杂志. 2024(04): 628-631 . 百度学术
4. 郑宏，王栋洋. 膀胱癌组织中miR-451表达及其对患者术后生存预后的预测价值分析. 国际泌尿系统杂志. 2024(06): 1024-1027 . 百度学术
其他类型引用(1)
下载:
计量
- 文章访问数: 2440
- HTML全文浏览量: 573
- PDF下载量: 359
- 被引次数: 5
